AI-Assisted IntelligenceUpdated

The AI knowledge layer for GLP-1 therapy.

Ask anything about Semaglutide, Tirzepatide, and metabolic health — get sourced, conversational answers.

Aligned with NIH · Mayo Clinic · FDA · peer-reviewed clinical literature

Knowledge layer · 04 sections

What you actually need to know

Structured for fast reading and AI extraction. Each block ends with a one-line takeaway.

01Foundations

GLP-1 basics

Key insight

GLP-1 medications reduce appetite by amplifying the body's natural hormonal hunger signals.

Read the foundations
03Experience timeline

What progression actually looks like

Key insight

Most users see noticeable appetite changes within two weeks and measurable weight loss by week six.

See full timeline
04Eligibility & decision

Who GLP-1 therapy is for

Key insight

GLP-1 therapy is a long-term metabolic intervention, not a short-term fix — eligibility and sustainability both matter.

Find your journey
Decision support

Tools that actually help you decide.

Assistant→
Ask GLP-1 AI

Conversational answers across medications, dosing, nutrition, and side effects.

Interactive→
Side Effect Navigator

Pick a symptom — see what's normal, what helps, and when to call your prescriber.

Tool→
Journey Estimator

Visualize your expected trajectory based on STEP-1 and SURMOUNT-1 trial data.

Library→
Answer Hub

Direct, sourced answers to the most-asked GLP-1 questions.

Comparison micro-engine

Semaglutide vs Tirzepatide

The four differences that actually drive a treatment decision.

Mechanism

Semaglutide

GLP-1 agonist (single)

Tirzepatide

GLP-1 + GIP agonist (dual)

Average weight loss

Semaglutide

~15% (STEP-1, 68 wks)

Tirzepatide

~22% (SURMOUNT-1, 72 wks)

Cost tendency

Semaglutide

Lower list price, broader coverage

Tirzepatide

Higher list price, growing coverage

Typical effect

Semaglutide

Steady appetite reduction

Tirzepatide

Stronger appetite + metabolic effect

Key insight: Tirzepatide tends to produce greater weight loss; semaglutide remains more accessible.

Full clinical breakdown →
Experience timeline

The typical progression

A simplified view of what most users experience across the first 90 days.

  1. 01Week 1–2

    Appetite changes

    Hunger signals soften within days. Mild nausea is common as the body adapts to the starting dose.

  2. 02Week 3–6

    Weight trend begins

    As the dose escalates, measurable weight loss appears. Hydration and protein intake matter most here.

  3. 03Week 6–12

    Possible plateaus

    Loss may slow as the body recalibrates. Plateaus are expected and rarely a sign of failure.

  4. 04Month 3+

    Stabilization

    Weight stabilizes at a new metabolic set point. Long-term success depends on lifestyle alignment.

Key insight: Appetite changes appear first; meaningful weight change typically becomes visible between weeks 3 and 6.

Medical-grade structured information

Every claim maps to a citation, dose range, or trial reference — cross-referenced with FDA post-market safety reports and NIH/NIDDK clinical guidance, not opinion.

Aligned with public clinical research

Built on PubMed, FDA labels, and reference material from the NIH, Mayo Clinic, and Cleveland Clinic.

Reviewed and updated regularly

Content is re-checked against new trial data and label changes each cycle, including ongoing updates from the CDC and the NIDDK weight-management library.

Next step

Where to go from here

Get a personalized guide

Answer a few questions and receive a tailored starting framework.

Start guide

Ask the AI assistant

Conversational answers sourced from vetted clinical literature.

Ask anything

Track progress insights

Understand plateaus, side-effect patterns, and titration timing.

Explore insights

Conversational
Intelligence.

Our platform is built on an LLM fine-tuned on vetted medical journals — not forum speculation. Search for facts, not opinions.

Medically reviewed monthly

Does GLP-1 medication work without changing diet?

+

GLP-1 medications reduce appetite on their own, so some weight loss occurs without dietary changes. However, sustained outcomes in the STEP-1 trial and SURMOUNT-1 consistently pair the medication with adequate protein, resistance training, and structured nutrition, as also emphasized by the NIH/NIDDK.

How fast does weight loss start on GLP-1 therapy?

+

Appetite changes usually appear within the first 1–2 weeks, as documented in the FDA Wegovy prescribing information. Measurable weight loss typically becomes visible between weeks 3 and 6 as the dose is titrated up — a trajectory mirrored in Mayo Clinic patient information. The first 12 weeks reflect adaptation more than final response.

What are the most common side effects?

+

Nausea, mild constipation or diarrhea, fatigue, and reduced appetite are the most reported in PubMed systematic reviews of GLP-1 GI adverse events. Most are mild-to-moderate, occur during dose escalation, and resolve as the body adapts. Severe or persistent symptoms — especially those flagged by Cleveland Clinic and the FDA — should be reviewed clinically.

What happens after stopping GLP-1 medication?

+

STEP-4 trial data (PubMed) shows significant weight regain after discontinuation when not paired with a structured lifestyle transition. GLP-1 therapy is currently treated by clinical references such as the NIDDK as long-term metabolic care, not a short-term intervention.

What is the main difference between Semaglutide and Tirzepatide?

+

Semaglutide is a selective GLP-1 receptor agonist (see the FDA Wegovy label); Tirzepatide acts on both GLP-1 and GIP receptors (see the FDA Mounjaro label). The dual mechanism produces greater average weight loss in head-to-head trial data on PubMed, though semaglutide remains more broadly covered by insurance.

How does the AI verify clinical claims?

+

Answers are cross-referenced with PubMed, FDA drug labels, and guidelines from the NIH and Mayo Clinic. Citations are embedded in the conversational output so each claim is traceable.

AI-generated insights updated regularly · Last reviewed